ASP Isotopes Announces Proposed Public Offering of Common Stock
12 July 2024 - 6:01AM
ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”)
today announced that it has commenced an underwritten public
offering of shares of its common stock. ASP Isotopes intends to
grant the underwriters a 30-day option to purchase up to an
additional 15% of the number of shares of its common stock sold in
the offering. All of the shares in the offering are to be sold by
ASP Isotopes. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed or as to the actual size or terms of the
offering.
Canaccord Genuity is acting as sole bookrunner for the proposed
offering.
A shelf registration statement on Form S-3 relating to
these securities has been filed with the Securities and Exchange
Commission (SEC) and has been declared effective by the SEC. The
proposed offering is being made only by means of a prospectus and a
related prospectus supplement. These documents are or will be
available on the SEC’s website at www.sec.gov. Copies of the
preliminary prospectus supplement, dated July 11, 2024, and the
accompanying prospectus, dated June 12, 2024, relating to the
proposed offering may also be obtained by contacting Canaccord
Genuity LLC, Attention: Syndication Department, 1 Post Office
Square, 30th Floor, Boston, MA 02109, or by email at
prospectus@cgf.com. The final terms of the offering will be
disclosed in a final prospectus supplement to be filed with the
SEC.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About ASP Isotopes
ASP Isotopes Inc. is a development stage advanced materials
company dedicated to the development of technology and processes to
produce isotopes for use in multiple industries. The Company
employs proprietary technology, the Aerodynamic Separation Process
(“ASP technology”). The Company’s initial focus is on producing and
commercializing highly enriched isotopes for the healthcare and
technology industries. The Company also plans to enrich isotopes
for the nuclear energy sector using Quantum Enrichment technology
that the Company is developing. The Company has isotope enrichment
facilities in Pretoria, South Africa, dedicated to the enrichment
of isotopes of elements with a low atomic mass (light
isotopes).
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include, but are not limited to, those regarding ASP
Isotopes’ plans to consummate its proposed public offering and the
anticipated final terms, timing and completion of the proposed
offering. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “hope,” “may,” “plan,” “possible,”
“potential,” “predict,” “project,” “should,” “target,” “would” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual
events or results to differ materially from current expectations
and beliefs, including, but not limited to: risks and uncertainties
related to whether or not ASP Isotopes will be able to raise
capital through the sale of shares of common stock, the final terms
of the proposed offering, market and other conditions, the
satisfaction of customary closing conditions related to the
proposed public offering, the impact of general economic, industry
or political conditions in the United States or internationally and
other important risk factors set forth under the caption “Risk
Factors” in the preliminary prospectus supplement filed with the
SEC, in ASP Isotopes’ Annual Report on Form 10-K for the year
ended December 31, 2023 and in any other subsequent filings
made with the SEC by ASP Isotopes. There can be no assurance that
ASP Isotopes will be able to complete the proposed public offering
on the anticipated terms, or at all. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and ASP Isotopes specifically disclaims any obligation to update
any forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by
law.
Contacts
Jason Assad– Investor relationsEmail:
Jassad@aspisotopes.comTelephone: 561-709-3043
ASP Isotopes (NASDAQ:ASPI)
Historical Stock Chart
From Dec 2024 to Jan 2025
ASP Isotopes (NASDAQ:ASPI)
Historical Stock Chart
From Jan 2024 to Jan 2025